IP Library Granted Patent US 10,590,412
Granted Patent B2
US 10,590,412 · App. 14/785,411 · Granted Mar 17, 2020

Compositions and methods for modulation nucleic acids through nonsense mediated decay

Inventors: Amanda Ward (Cambridge, MA); Frank Rigo (Carlsbad, CA)
Assignee: Ionis Pharmaceuticals, Inc.
C12N15/113C12N2310/11C12N2310/321C12N2310/322C12N2310/3231C12N2310/3341C12N2310/346C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,412
App. No.
14/785,411
Granted
Mar 17, 2020
Kind
B2
Abstract

Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid. In certain embodiments, the amount or activity of a target nucleic acid is modulated through nonsense mediated decay.

Claims (17)

1. A method of reducing the amount or activity of a target mRNA that encodes a protein selected from STAT3, SOD1, and HNRNPH1 in a cell through nonsense mediated decay, comprising contacting a cell with an oligomeric compound comprising a modified oligonucleotide, wherein:

the modified oligonucleotide consists of 10 to 30 linked nucleosides,

wherein each nucleoside of the modified oligonucleotide comprises a 2′-MOE modified nucleoside; or the modified oligonucleotide has an A-B 2 -A-B 2 -A-B 2 -A-B 2 -A-B 2 -A motif or an A 2 -B 2 -A-B 2 -A-B 2 -A-B 2 -A-B 2 -A 2 motif, wherein each A comprises a bicyclic sugar moiety, and wherein each B comprises a sugar moiety selected from a 2′-substituted sugar moiety and an unmodified 2′-deoxy sugar moiety,

wherein each internucleoside linkage in the modified oligonucleotide is a phosphorothioate internucleoside linkage, and

wherein the modified oligonucleotide is at least 90% complementary to a pre-mRNA corresponding to the target mRNA;

wherein the oligomeric compound increases exclusion of an exon from the target mRNA and thereby introduces a premature termination codon in the target mRNA; and wherein the target mRNA with the premature termination codon is recognized by the nonsense mediated decay mechanism, thereby reducing the amount or activity of the target mRNA in the cell through nonsense mediated decay.

2. The method of claim 1 , wherein each modified nucleoside comprises a 2′-MOE sugar moiety.

3. The method of claim 1 , wherein the modified oligonucleotide has an A-B 2 -A-B 2 -A-B 2 -A-B 2 -A-B 2 -A motif, wherein each A comprises a bicyclic sugar moiety, and wherein each B comprises a sugar moiety selected from a 2′-substituted sugar moiety and an unmodified 2′-deoxy sugar moiety.

4. The method of claim 1 , wherein each A comprises a cEt sugar moiety or an LNA sugar moiety.

5. The method of claim 3 , wherein each A comprises a cEt sugar moiety or an LNA sugar moiety.

6. The method of claim 1 , wherein each B comprises an unmodified 2′-deoxy sugar moiety or a 2′-MOE sugar moiety.

7. The method of claim 3 , wherein each B comprises an unmodified 2′-deoxy sugar moiety or a 2′-MOE sugar moiety.

8. The method of claim 1 , wherein the cell is in an animal.

9. The method of claim 4 , wherein each B comprises an unmodified 2′-deoxy sugar moiety.

10. The method of claim 5 , wherein each B comprises an unmodified 2′-deoxy sugar moiety.

11. The method of claim 1 , wherein the modified oligonucleotide has an A 2 -B 2 -A-B 2 -A-B 2 -A-B 2 -A-B 2 -A 2 motif, wherein each A comprises a bicyclic sugar moiety, and wherein each B comprises a sugar moiety selected from a 2′-substituted sugar moiety and an unmodified 2′-deoxy sugar moiety.

12. The method of claim 1 , wherein each cytosine in the modified oligonucleotide is a 5-methyl cytosine.

Assignments (1)
CHANGE OF NAME Recorded Feb 22, 2016
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 037880/0397 →
Continuity (3)
Provisional Application 61946591 · Feb 28, 2014
Provisional Application 61814139 · Apr 19, 2013
Related Publication 20160076027A1 · Mar 17, 2016